142 related articles for article (PubMed ID: 12612964)
1. Renal osteodystrophy: role of calcimimetics.
Hörl WH
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S104-7. PubMed ID: 12612964
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Prevention of uremic bone disease using calcimimetic compounds.
Olgaard K; Lewin E
Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775
[TBL] [Abstract][Full Text] [Related]
4. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
5. Are new vitamin D analogues in renal bone disease superior to calcitriol?
Salusky IB
Pediatr Nephrol; 2005 Mar; 20(3):393-8. PubMed ID: 15690188
[TBL] [Abstract][Full Text] [Related]
6. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K
Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316
[TBL] [Abstract][Full Text] [Related]
7. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism.
Fox J; Lowe SH; Conklin RL; Nemeth EF
Endocrine; 1999 Apr; 10(2):97-103. PubMed ID: 10451217
[TBL] [Abstract][Full Text] [Related]
8. Renal osteodystrophy: review of the disease and its treatment.
El-Kishawi AM; El-Nahas AM
Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):373-82. PubMed ID: 16970258
[TBL] [Abstract][Full Text] [Related]
9. Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro.
Almaden Y; Rodriguez-Ortiz ME; Canalejo A; Cañadillas S; Canalejo R; Martin D; Aguilera-Tejero E; Rodríguez M
J Nephrol; 2009; 22(2):281-8. PubMed ID: 19384847
[TBL] [Abstract][Full Text] [Related]
10. [Vitamin D therapy in renal osteodystrophy].
Tsukamoto Y
Clin Calcium; 2004 Sep; 14(9):21-6. PubMed ID: 15577105
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
12. The molecular basis of secondary hyperparathyroidism in chronic renal failure.
Rahamimov R; Silver J
Isr J Med Sci; 1994 Jan; 30(1):26-31. PubMed ID: 8138394
[TBL] [Abstract][Full Text] [Related]
13. Marked improvement in parameters of renal osteodystrophy with the use of intraperitoneal calcitriol.
Arora N; Sandroni S; Moles K
Adv Perit Dial; 1992; 8():62-4. PubMed ID: 1361854
[TBL] [Abstract][Full Text] [Related]
14. Renal osteodystrophy in children with end-stage kidney failure.
Chan JC
Va Med; 1979 May; 106(5):384-90. PubMed ID: 463255
[TBL] [Abstract][Full Text] [Related]
15. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
Lindberg JS
Kidney Int Suppl; 2005 Jun; (95):S33-6. PubMed ID: 15882311
[TBL] [Abstract][Full Text] [Related]
16. Zinc nutritional status modifies renal osteodystrophy in uremic rats.
Kimmel PL; Langman CB; Bognar B; Faugere MC; Chawla LS; Watkins DW; Malluche HH
Clin Nephrol; 2001 Dec; 56(6):445-58. PubMed ID: 11770796
[TBL] [Abstract][Full Text] [Related]
17. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy.
Hernandez JD; Wesseling K; Salusky IB
Semin Dial; 2005; 18(4):290-5. PubMed ID: 16076350
[TBL] [Abstract][Full Text] [Related]
18. Effects of treatment of renal osteodystrophy on bone histology.
Malluche HH; Mawad H; Monier-Faugere MC
Clin J Am Soc Nephrol; 2008 Nov; 3 Suppl 3(Suppl 3):S157-63. PubMed ID: 18988701
[TBL] [Abstract][Full Text] [Related]
19. Understanding and managing hyperphosphatemia in patients with chronic renal disease.
Malluche HH; Monier-Faugere MC
Clin Nephrol; 1999 Nov; 52(5):267-77. PubMed ID: 10584989
[TBL] [Abstract][Full Text] [Related]
20. Control of parathyroid function in patients with a short history of hemodialysis.
Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
